Sofituzumab vedotin
Catalog No.: PC0136
Size: 1 mg, 5 mg
Description
Sofituzumab vedotin (DMUC5754A) is an MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin is used in cancer research.
| CAS No. |
1418200-58-4 |
| Shipping |
Room temperature in continental US; may vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| In Vitro |
Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl.
Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner. |
| In Vivo |
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models. |
All of our services are intended for preclinical research
use only and cannot be used to diagnose, treat or manage patients.
